Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 19, 2014

Primary Completion Date

January 10, 2015

Study Completion Date

January 19, 2015

Conditions

Type 2 Diabetes MellitusHepatic Impairment

Interventions

DRUG

Ertugliflozin 15 mg

Tablet